share_log

Capricor Therapeutics shares are trading higher. The company said it will provide an update on recent findings after a preliminary review of its ongoing open-label extension study of the Phase II HOPE

Benzinga ·  Jun 17, 2021 10:59
Capricor Therapeutics shares are trading higher. The company said it will provide an update on recent findings after a preliminary review of its ongoing open-label extension study of the Phase II HOPE-2 trial with lead asset, CAP-1002 at PPMD 2021.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment